Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity

Published on: 

Biomanufacturing capacity expansion uses modular cleanroom design and single-use technologies.

Avid Bioservices, the contract-manufacturing subsidiary of Peregrine Pharmaceuticals, has initiated an expansion of its biomanufacturing capacity for clinical and commercial manufacturing services. The new production facility will more than double the company's current manufacturing capacity and will use a flexible modular cleanroom design and single-use technologies.

The capacity expansion will take place within an existing 40,000-ft2 warehouse located adjacent to the company's current campus in California. The new cGMP facility will accommodate multiple single-use bioreactors of up to 2000 liters, downstream processing suites, and dedicated support utilities that will allow for the production of a variety of biological products.

"As one of the early adopters of single-use technology, this expansion allows us to build upon our expertise in what is now a common mainstream practice for biologics production," said Steven King, president at Avid.


"This will truly be a cutting-edge facility utilizing a leading trend in biomanufacturing in terms of flexibility and efficiency," said Robert Garnick, PhD, head of regulatory affairs at Peregrine. "We have been pleased that the design, the flow, as well as equipment and timelines, have all been well received by leaders and experts in biomanufacturing. We look forward to having this facility build upon our exemplary inspection and audit record that Avid has achieved from multiple regulatory agencies."

Source:  Peregrine Pharmaceuticals